SDZNY

Health Care Roundup: Market Talk

Read about CVS, Kenvue, Fresenius Medical and more in the latest Market Talks covering the Health Care sector....

Sandoz reports first quarter 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in U...

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmedMathai Mammen, Graeme Pitkethly and Mi...

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears pa...

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program confirming...

Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.